Niagen Bioscience (NAGE) Insider Ann Cohen Buys 31,746 Shares
Insider Ann Cohen acquired shares of Niagen Bioscience on June 24, 2026.
Reviewed by automated data checks against the source filing. How we make and check alerts
Ann Cohen bought 31,746 shares of Niagen Bioscience, Inc. ($NAGE) on June 24, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $NAGE is down 3.5% after 1 week, down 7.0% after 1 month and down 27.8% to date (from the $3.45 close on Jun 24, 2026).
NAGE
Niagen Bioscience, Inc.
Key Points
- Ann Cohen purchased 31,746 shares of Niagen Bioscience on June 24, 2026, at a price of $3.42 per share.
- Niagen Bioscience has a market cap of about $240.5 million and a P/E ratio of 16.0.
- The company is set to report its next earnings on November 3, 2026.
Get $NAGE trade alerts by text
We text you when insiders, Congress or big funds trade $NAGE. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Niagen Bioscience, Inc. alert may contain errors. Disclosures
Insider Buying and Selling at Niagen Bioscience, Inc.
On June 24, 2026, Ann Cohen bought 31,746 shares of Niagen Bioscience, Inc. (NAGE) on the NasdaqCM at a price of $3.42 per share. This purchase reflects her confidence in the company, which specializes in developing healthy aging products.
Other Insiders Also Buying
Cohen wasn't alone in her purchase. On the same day, several other insiders at Niagen Bioscience also bought 31,746 shares each. These include Yu Wing Tak Wendy, Hamed Shahbazi, Steven Rubin, Kristin Patrick, and Ng Wang Yu Gary. Each of these transactions indicates a collective belief in the company's future.
How NAGE Stock Has Traded
Niagen Bioscience shares are currently trading around $3.42, a price that is above its 52-week low of $2.87 but well below its high of $10.52. The stock's current price suggests that it is experiencing some volatility, which could present buying opportunities for investors.
What NAGE Does
Niagen Bioscience, Inc. is based in Los Angeles and focuses on products that promote healthy aging. The company sells dietary supplements and ingredients that support cellular metabolism, which is a growing area of interest in the health industry.
What's Next for NAGE
Looking ahead, Niagen Bioscience is expected to release its earnings report on November 3, 2026. This will provide further insights into the company's performance and may influence future trading activity. The recent insider buying, including Cohen's, suggests that those close to the company are optimistic about its prospects. Remember, the reported trades reflect past positions and may not indicate current holdings.
Related Filing Alerts
Source: Ann Cohen's Form 4 filing on $NAGE (Jun 24, 2026). Find the original filing: NAGE Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts